Patents Assigned to SinoCellTech Ltd.
  • Patent number: 12275790
    Abstract: The present disclosure provides a recombinant humanized monoclonal antibody against programmed cell death receptor-1 (PD-1) or an antigen-binding fragment thereof, which can be used in tumor or cancer immunotherapy. The disclosure also provides nucleic acid sequences encoding said antibody or antigen-binding fragment thereof, vectors containing said nucleic acid sequences, pharmaceutical compositions and kits.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 15, 2025
    Assignee: SinoCellTech Ltd.
    Inventors: Liangzhi Xie, Chunyun Sun, Juan Ma
  • Patent number: 12139514
    Abstract: The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: November 12, 2024
    Assignee: SINOCELLTECH LTD.
    Inventors: Liangzhi Xie, Chunxia Luo, Wei Zhang, Xiaoyan Suo, Lin Pang, Ping Hu
  • Patent number: 12060416
    Abstract: The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibodies, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The antibody disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2. Said antibodies also neutralize the proliferative effect of VEGF165 protein and multiple VEGF subtypes on HUVEC cells and can be used in clinical treatment of tumors, including but not limited to: colorectal cancer.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: August 13, 2024
    Assignee: SinoCellTech Ltd.
    Inventors: Liangzhi Xie, Chunyun Sun, Rui Wang, Xiao Zhang